About the speaker
Dr. Marina Udier has been the Chief Executive Officer of Nouscom AG since 2016, where she has been responsible for all aspects of company’s business development, business operations and finance activities. Marina joined Nouscom as an Operating Principal from Versant Ventures. During her tenure with the Versant investment team, she identified new investment opportunities in Europe and worked with portfolio companies in Europe and US.
Prior to Versant, Marina was in various senior development and commercial roles at Novartis Pharma. As the Global Commercial Head, Near Patient Testing Unit, she developed global commercial strategy and launch plans for a point of care diagnostics platform. Marina led development and subsequent registration of a Companion Diagnostics (In Vitro Diagnostics) for RYDAPT™ (midostaurin), the first approved AML drug in over 3 decades. She managed the Global commercial Neurodegeneration portfolio for Novartis driving her Brands to a blockbuster status.
Marina spent 5 years with McKinsey & Company in Chicago, working with Healthcare Fortune 500 companies, specializing in areas of marketing and strategy. Marina received her PhD in Chemistry from Yale University. She authored several peer reviewed publications in the area of HIV/AIDS research.